Eyerising Myopia Management Device by Eyerising International, is the world first at-home red-light therapy device aimed to slow the progression of childhood myopia. Repeated low-level red-light (RLRL) therapy has been used in the treatment of various medical conditions for almost half century. It’s now been shown that controlled exposure to low-level single wavelength red-light can prevent or slow down the progression of myopia.

Features and Benefits:

• Non-invasive
• No drugs
• No injections
• No specialised lenses and no risk of infection
• No significant side effects
• Suitable and easily tolerated by children as young as 3 years.
• Comprehensive patient compliance data provided to clinicians for use in patient examinations

Safety and Efficacy proven in multi-centre randomized clinical trials, and published in prestigious scientific magazines.

Eyerising Myopia Management Device has been cleared as a medical device by the following regulators: CFDA (China), CE (EU), TGA (Australia), Medsafe (NZ) and MHRA (UK) and is ISO 13485 certified.